Lakefront Biotherapeutics (LKFT) Cash from Discontinued Operations (2018 - 2026)

Lakefront Biotherapeutics (LKFT) has 6 years of Cash from Discontinued Operations data on file, last reported at 709471.86 in Q1 2026.

• Cash from Discontinued Operations for Q1 2026 came in at 709471.86, down 41.35% year-over-year; the trailing twelve-month figure through Mar 2026 was 213837679.85 (changed N/A YoY), and the FY2021 annual result was 576363452.4, changed N/A from the prior year.
• Cash from Discontinued Operations retreated to 709471.86 in Q1 2026 per LKFT's latest filing, from 1209667.11 in the prior quarter.
• Over five years, Cash from Discontinued Operations peaked at 1209667.11 in Q1 2025 and troughed at 69550146.07 in Q1 2022.
• A 3-year average of 22543669.03 and a median of 709471.86 in 2026 frame the typical range for Cash from Discontinued Operations.
• The sharpest annual moves came in 2022 and 2026: Cash from Discontinued Operations surged 52.43% in 2022, then tumbled 41.35% in 2026.
• A 3-year view of Cash from Discontinued Operations shows it stood at 69550146.07 in 2022, then soared by 101.74% to 1209667.11 in 2025, then plunged by 41.35% to 709471.86 in 2026.
• Business Quant data shows LKFT's Cash from Discontinued Operations at 709471.86 in Q1 2026, 1209667.11 in Q1 2025, and 69550146.07 in Q1 2022.